Gan & Lee Pharmaceuticals. (SHA:603087)

SHA:603087 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,091	902.78	2,443	2,890	3,306	2,825
Short-Term Investments	-	-	-	201.36	276.44	945.34
Trading Asset Securities	1,146	1,500	2,410	1,636	1,624	787.05
Cash & Short-Term Investments	2,237	2,403	4,853	4,728	5,206	4,557
Cash Growth	-54.05%	-50.48%	2.66%	-9.20%	14.24%	161.44%
Accounts Receivable	504.58	213.71	383.74	189.57	934.66	827.35
Other Receivables	7.72	31.89	1.63	0.99	0.16	0.96
Receivables	512.29	245.6	385.37	190.55	934.82	828.3
Inventory	1,115	1,053	860.51	648.65	651.33	493.48
Other Current Assets	101.82	89.07	76.73	97.36	77.95	80.55
Total Current Assets	3,966	3,791	6,176	5,664	6,870	5,960
Property, Plant & Equipment	3,840	3,882	3,886	3,661	2,595	2,149
Long-Term Investments	504.4	497.03	304.66	30	201.36	466.05
Other Intangible Assets	264.27	273.06	278.08	293.48	295.99	238.92
Long-Term Deferred Tax Assets	220.87	206.94	168.95	138.25	30.8	14.93
Long-Term Deferred Charges	1,211	924.91	821.97	743.19	588.87	544.27
Other Long-Term Assets	1,871	2,468	79.99	76.51	270.33	134.67
Total Assets	11,878	12,043	11,715	10,607	10,853	9,507
Accounts Payable	92	115.61	94.82	36.52	26.15	14.79
Accrued Expenses	176.35	183.44	192.54	190	173.04	183.07
Current Portion of Leases	1.13	1.33	2.18	5.69	5.07	-
Current Income Taxes Payable	1.5	1.49	1.42	1.35	106.32	53.35
Current Unearned Revenue	55.26	63.25	52.99	68.13	36.56	68.44
Other Current Liabilities	408.83	436	429.49	511.36	138.39	90.19
Total Current Liabilities	735.07	801.13	773.45	813.04	485.53	409.85
Long-Term Leases	2.8	3.31	5.45	8.33	12.17	-
Long-Term Unearned Revenue	166.99	168.92	179.63	187.63	141.98	125.77
Long-Term Deferred Tax Liabilities	5.05	12.11	-	-	36.15	31.78
Other Long-Term Liabilities	2.65	2.97	14	12.27	10.2	1.69
Total Liabilities	912.56	988.45	972.52	1,021	686.02	569.09
Common Stock	601.07	601.07	594.16	565.65	561.54	561.54
Additional Paid-In Capital	3,631	3,591	3,351	2,563	2,476	2,474
Retained Earnings	7,065	7,059	6,865	6,525	7,133	5,905
Treasury Stock	-335.8	-200.85	-71.36	-71.36	-	-
Comprehensive Income & Other	4.02	4.04	3.82	3.44	-3.44	-1.55
Total Common Equity	10,965	11,054	10,743	9,586	10,167	8,939
Minority Interest	-	-	0	-0.16	-0.16	-0.16
Shareholders' Equity	10,965	11,054	10,743	9,586	10,167	8,938
Total Liabilities & Equity	11,878	12,043	11,715	10,607	10,853	9,507
Total Debt	3.94	4.64	7.62	14.01	17.24	-
Net Cash (Debt)	2,233	2,399	4,846	4,714	5,189	4,557
Net Cash Growth	-54.09%	-50.50%	2.80%	-9.16%	13.86%	161.44%
Net Cash Per Share	3.76	4.06	8.55	8.37	9.25	8.55
Filing Date Shares Outstanding	595.16	598.96	590.05	561.54	561.54	561.54
Total Common Shares Outstanding	595.16	598.96	590.05	561.54	561.54	561.54
Working Capital	3,231	2,990	5,402	4,851	6,385	5,550
Book Value Per Share	18.42	18.46	18.21	17.07	18.11	15.92
Tangible Book Value	10,701	10,781	10,464	9,292	9,871	8,700
Tangible Book Value Per Share	17.98	18.00	17.73	16.55	17.58	15.49
Buildings	2,152	2,137	1,344	1,165	1,046	1,013
Machinery	1,678	1,601	1,443	1,237	1,263	1,171
Construction In Progress	1,260	1,262	2,007	2,003	874.91	410.12

Updated Oct 30, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.